Skip to main content

Advertisement

Table 1 Patients baseline characteristics

From: Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients

  Male Female
Number of patients 14 22
Enzyme activity (Agal U)a 3.9 ± 1.2   15.2 ± 6.6  
Onset (y.o.)a 7.7 ± 7.7   13.5 ± 10.7  
Age (y.o.)a 26.6 ± 10.4   45.4 ± 16.4  
  N ( % ) N ( % )
Pain attack 11 ( 78.6 ) 6 ( 27.3 )
Angiokeratoma 7 ( 50 ) 4 ( 18.2 )
Hypohidrosis 10 ( 71.4 ) 4 ( 18.2 )
Depression 1 ( 7.1 ) 3 ( 13.6 )
Stroke 2 ( 14.3 ) 2 ( 9.1 )
Corneal opacity 10 ( 71.4 ) 16 ( 72.7 )
Tinnitus 6 ( 42.9 ) 4 ( 18.2 )
Dizziness 0 ( 0 ) 5 ( 22.7 )
Diarrhea 7 ( 50 ) 8 ( 36.4 )
Hypertension 1 ( 7.1 ) 1 ( 4.5 )
Angina 3 ( 21.4 ) 3 ( 13.6 )
LVHb 1 ( 7.1 ) 9 ( 40.9 )
Proteinuria 5 ( 35.7 ) 4 ( 18.2 )
Renal failure 0 ( 0 ) 2 ( 9.1 )
  1. amean ± SD, b LVH Left ventricular hypertrophy